Skip to main content

Table 2 RNAseq comparing no treatment controls versus 18 h treatment with: a.) control versus MP1 at 500 nM, b.) control versus TEM alone at 1 μM, and c) control versus combination of MP1 plus TEM. All treatments were performed in triplicate and fold change calculated from the ratio of treatment over control

From: Effects of novel pyrrolomycin MP1 in MYCN amplified chemoresistant neuroblastoma cell lines alone and combined with temsirolimus

a.)
Gene Change p-value Cntrl#1 Cntrl#2 Cntrl #3 MP1#1 MP1#2 MP1#3
MYCN −2.0 6.09 E-179 2125 2166 2202 1092 1087 1096
 MCL-1 −1.18 3.38E-09 318 309 315 265 268 267
 LCII + 1.8 4.08 E-59 67.5 70.7 76.0 135 128.9 131.4
 LCI + 1.6 1.38 E-03 2.68 3.8 2.67 4.23 6.13 4.27
 PARP1 −1.5 8.56 E-52 699 711.6 689.6 451.8 466.3 463.9
 BRD-4 + 1.07 0.15 77.3 75.5 75.2 84.5 82.2 77.4
 Bcl-2 1.76 1.09 E-35 33.7 34.6 34.1 64.0 50.5 56.9
 BAX −1.39 8.51 E-12 46.1 47.6 43.4 35.0 31.5 32.0
b.)
Gene Change p-value Cntrl#1 Cntrl #2 Cntrl #3 TEM#1 TEM#2 TEM#3
 MYCN 1.0 0.35 2125 2166 2202 2264 2140 2232
 MCL-1 −1.12 2.48E-05 318 309 315 281 282 276
 LCII + 1.3 1.44 E-10 67.5 70.7 76.0 92.7 92.5 89.7
 LCI + 1.5 0.004 2.68 3.8 2.67 5.1 4.4 4.4
 PARP1 −1.2 1.01E-08 699 712 690 580 617 599
 BRD-4 −1.06 0.20 77.3 75.5 75.2 70.4 71.4 72.7
 Bcl-2 1.45 9.03 E-16 33.7 34.6 34.1 49.2 52.0 47.7
 BAX −1.14 0.007 46.1 47.6 43.4 42.7 37.3 40.6
c.)
Gene Change p-value Cntrl#1 Cntrl #2 Cntrl #3 MP1 + TEM #1 MP1 + TEM #2 MP1 + TEM #3
 MYCN −1.6 9.1E-89 2125 2166 2202 1338 1347 1356
 MCL-1 −1.2 1.29E-08 318 309 315 266 271 269
 LCII + 1.7 2.28 E-42 67.5 70.7 76.0 113 125 120
 LCI + 2.5 2.11E11 2.68 3.8 2.67 8.19 8.21 6.5
 PARP1 −1.6 6.48E-64 699 712 690 432 440 447
 BRD-4 −1.09 0.078 77.3 75.5 75.2 78.6 62.5 68.8
 Bcl-2 1.94 5.9 E-51 33.7 34.6 34.1 66.2 63.8 68.5
 BAX −1.29 8.67 E-08 46.1 47.6 43.4 34.3 36.5 35.8
\